MedPath

Neuromolecular Risk Factors for Obesity (PROSPECT)

Not Applicable
Conditions
Obesity
Interventions
Diagnostic Test: fMRI imaging
Diagnostic Test: [11C]carfentanil PET scan
Diagnostic Test: [18F]FMPEP-d2 PET scan
Diagnostic Test: [18F]-FDG PET scan
Diagnostic Test: Physical activity measures and fitness tests
Diagnostic Test: Laboratory measurements
Diagnostic Test: Questionnaires
Diagnostic Test: Hyperinsulinemic euglycemic clamp
Registration Number
NCT03106688
Lead Sponsor
Turku University Hospital
Brief Summary

The goal of this project is to characterize the neural and psychological mechanisms that contribute to development of obesity in the early adulthood. We address the neuromolecular risk factors for obesity using multi-modal molecular (positron emission tomography with) and functional (functional magnetic resonance imaging) neuroimaging in a prospective design. Normal weight adolescents with high versus low familial, genetic and psychological risk factors for obesity will be studied and followed for five years.

Detailed Description

Diet, nutrition, and physical exercise are critical factors in the maintenance of good health through the entire life course. However, in most western countries the annual increase in the prevalence and the severity of obesity and physical inactivity is substantial. Early detection of individuals with high risk for obesity is important, because reversing the obese state is very difficult. To prevent and treat obesity, it is necessary to characterize neural mechanisms supporting altered incentive motivation and food intake, and to build a comprehensive model of the interactions between neural, physiological, and psychological factors contributing to development and maintenance of obesity. This obviously calls for novel data analysis techniques allowing fusion analysis of neurobiological, physiological, and behavioural data, as well as screening the critical combination of biomarkers for obesity.

A total of sixty males (30 normal-weight, 30 with risk for developing obesity) are recruited into this prospective study. The subjects will undergo physical examination, physical fitness tests, physical activity measures, body tissue composition measurement, structural and functional magnetic resonance imaging of the brain and body (MRI \& fMRI), and positron emission tomography (PET) with ligands \[18F\]-fluorodeoxyglucose (\[18F\]-FDG), \[18-F\]FMPEP, and \[11C\]carfentanil. Subjects' weight and physical condition will be followed up for 5 years.

In three interconnected work packages (WPs) we test three hypotheses derived from human and animal studies:

1. Altered reward and cognitive control functions in the brain predisposes some individuals to overeating and obesity.

2. Opioid system and reward circuit function provide feasible biomarkers for obesity risk.

3. Mobile tracking and behavioural paradigms tapping reward learning and inhibitory control can be used for unobtrusive and inexpensive detection of risk factors for obesity.

These studies will improve our understanding of the neural and psychological mechanisms of obesity and addictive disorders. This knowledge will translate into crucial knowledge for developing novel risk factor screening procedures, and novel pharmacological and psychological treatments for obesity.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
60
Inclusion Criteria

Inclusion criteria for low-risk group:

  • Male sex
  • Age 20-35 years
  • BMI 20-24 kg/m2
  • Physical exercise > 4 hrs per week
  • No maternal / paternal obesity OR maternal / paternal type 2 diabetes mellitus (T2DM)

Inclusion criteria for high-risk group:

  • Male sex
  • Age 20-35 years
  • BMI 25 - 30 kg/m2
  • Maternal / paternal obesity OR maternal / paternal T2DM
  • Physical exercise < 4 hrs per week
Exclusion Criteria
  • Any chronic disease or medication that could affect glucose metabolism or neurotransmission
  • History of anorexia nervosa, bulimia or other eating disorder (excl. common obesity)
  • Smoking of tobacco, taking of snuffs, or use of narcotics
  • Abusive use of alcohol
  • Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Low-risk group[11C]carfentanil PET scanIndividuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
Low-risk groupfMRI imagingIndividuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
Low-risk groupLaboratory measurementsIndividuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
High-risk group[18F]-FDG PET scanIndividuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
High-risk groupPhysical activity measures and fitness testsIndividuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
High-risk groupLaboratory measurementsIndividuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
Low-risk group[18F]-FDG PET scanIndividuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
Low-risk groupPhysical activity measures and fitness testsIndividuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
High-risk group[18F]FMPEP-d2 PET scanIndividuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
Low-risk group[18F]FMPEP-d2 PET scanIndividuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
High-risk group[11C]carfentanil PET scanIndividuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
High-risk groupQuestionnairesIndividuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
High-risk groupHyperinsulinemic euglycemic clampIndividuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
Low-risk groupQuestionnairesIndividuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
Low-risk groupHyperinsulinemic euglycemic clampIndividuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
High-risk groupfMRI imagingIndividuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
Primary Outcome Measures
NameTimeMethod
Neuromolecular risk score for weight gainWithin five study years

Acquired with combining the measured BMI change in five years to measured alterations in brain function (see below).

Secondary Outcome Measures
NameTimeMethod
BMI change in five yearsWithin five study years

Acquired with BMI of the study subjects measured in initial health check-up and once in every study year

Physical strengthWithin one study day

Total physical strenght score is calculated from 1) countermovement jump test with a contact mat (flight time measured - jump height calculated), hand grip strength (measured in Newtons), sit-ups (number of repetitions in 30 s), and back extension (reps in 30 s)

Brain and body glucose uptakeWithin one study day

Acquired with PET imaging

Brain MOR availabilityWithin one study day

Acquired with PET imaging

Behavioural patterns involving dysfunctional reward learning and inhibitory controlWithin one study year

Acquired with following questionnaires: assessment of leisure-time physical activity (LTPA), Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire, Pain Sensitivity Questionnaire, DASS-21, PSS-10

Body adiposityWithin one study day

Acquired with BodPod device (Frisard, Greenway, \& DeLany, 2005)

Genes regulating MOR (OPRM1) and D2R (DRD2) expressionWithin one study week

Acquired with whole blood sample and DNA/RNA analysis

Brain and body CB1 availabilityWithin one study day

Acquired with PET imaging

Localization of on-going neural activity during various cognitive and affective tasksWithin one study day

Acquired with fMRI imaging

Genetic risk score from all known obesity-risk genesWithin one study week

Acquired with whole blood sample and DNA/RNA analysis

Maximal physical performanceWithin one study day

The subjects will perform a maximal aerobic exercise test on a bicycle ergometer starting at the intensity of 50 W and followed by an increase of 30 W every 2 min until volitional exhaustion. Peak workload will be calculated as an average workload during the last 2 min of the test (weighted average will be used if the final stage is stopped prior the completion) and used as a measure of maximal performance of the subjects

Physical activity levelWithin one study week

Acquired with Polar M600 GPS Sports Watch that study subjects wear for the measurement period

Trial Locations

Locations (1)

Turku PET Centre (Turku University Hospital)

🇫🇮

Turku, Finland

© Copyright 2025. All Rights Reserved by MedPath